Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Leuk Lymphoma. 2013 Jul 29;54(10):2133–2143. doi: 10.3109/10428194.2013.783911

Table 2.

Cyclin dependent kinase inhibitors in clinical development.

Agent (alternative names) Targets Status*
Alvocidib (flavopiridol, HMR-1275,
L86-8275, NSC-649890)		 CDKs 1,2,4,6,7,9 Phase II
BAY-1000394 CDKs 1𠄴,7,9 Phase I
Dinaciclib (MK-7965, SCH-727965) CDKs 1,2,5,9 Phase III
P276-00 CDKs 1,4,9 Phase II
R547 CDKs 1,2,4 Phase I completed
Seliciclib (R-roscovitine, CYC-202) CDKs 1,2,5,7 Phase II terminated
SNS-032 (formerly BMS-387032) CDKs 2,7,9 Phase I completed
TG02 CDKs 1,2,7,9 FLT3, JAK2 Phase I